This site is intended for UK healthcare professionals

 

Supported

An educational walkthrough video to share with your patients referred to the National Amyloidosis Centre (NAC), providing an overview of what to expect during their visit. The video describes the range of investigations that may be undertaken at the NAC, and which healthcare professionals patients may meet at their appointment.

Funding for these videos has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

This short video outlines the role of the NAC (National Amyloidosis Centre) in managing patients you refer to them with suspected amyloidosis. It highlighting the use of accurate diagnostic testing techniques available at the NAC, including imaging, histology and proteomics, as well as the genetic testing and counselling that provide important components of holistic care.

Funding for these videos has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

Experts from the National Amyloidosis Centre in London examine three case studies, specifically focusing upon the symptoms that first aroused suspicion, the diagnostic tests that confirmed the condition, and the treatment options available to these patients.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Funding for this video has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.